HNSCC
Clinical trials for HNSCC explained in plain language.
Never miss a new study
Get alerted when new HNSCC trials appear
Sign up with your email to follow new studies for HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boost may help prevent head and neck cancer return
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard chemoradiation after surgery helps prevent cancer from coming back in people with advanced head and neck cancer. About 211 participants who had their tumor completely removed were randomly assigned …
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated May 17, 2026 09:21 UTC
-
Two-Drug immune attack shows promise against tough cancers
Disease control CompletedThis study tested a combination of two immune-boosting drugs (eftilagimod alpha and pembrolizumab) in 187 people with advanced lung cancer or head/neck cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors safely. Participan…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
New drug combo targets genetic weakness in head and neck cancer
Disease control CompletedThis study tested two drugs, tipifarnib and alpelisib, in 45 adults with advanced head and neck cancer that had spread or come back. The drugs target specific genetic changes in the tumor (HRAS or PIK3CA). The main goals were to check safety and find the best dose, while also see…
Matched conditions: HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 17, 2026 09:11 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had come back or spread. Participants were grouped based on whether they had tried these drugs before. The goal was to see if the combination could shri…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 17, 2026 09:11 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug called COM902, alone or with another drug (COM701), in 94 people with advanced cancers like ovarian, lung, colon, and multiple myeloma. The main goal was to check safety and find the best dose. While not a cure, the approach aims to contro…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested whether adding an experimental drug (eftilagimod alpha) to a standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that cannot be removed by surgery. About 171 adults with PD-L1 positive or negative tumors took part. The goal was…
Matched conditions: HNSCC
Phase: PHASE2 • Sponsor: Immutep S.A.S. • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Could a common supplement ease chemo pain? small trial hopes to find out
Symptom relief CompletedThis early-phase study tested alpha lipoic acid, a dietary supplement, in 5 adults with head and neck cancer undergoing chemoradiation. The goal was to find a safe dose that might reduce treatment-related pain and side effects. Researchers monitored for side effects and drug leve…
Matched conditions: HNSCC
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated May 11, 2026 20:47 UTC
-
Immunotherapy breakthrough: is one year enough?
Knowledge-focused CompletedThis study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…
Matched conditions: HNSCC
Phase: PHASE3 • Sponsor: Dan Zandberg • Aim: Knowledge-focused
Last updated May 07, 2026 18:41 UTC